Select a medication above to begin.
Glycyrrhiza glabra var. glandulifera
licorice (Glycyrrhiza glabra)
Entire Monograph
Reported Uses
- NOTE: see Herb & Supplement Effectiveness Rating Definitions table
- acne [Insufficient Evidence]
- Addison dz [Insufficient Evidence]
- adrenal insufficiency [Insufficient Evidence]
- allergic rhinitis [Insufficient Evidence]
- aphthous ulcer (canker sores) [Possibly Effective]
- atopic dermatitis (eczema) [Possibly Effective]
- bleeding [Insufficient Evidence]
- cancer-related pain [Insufficient Evidence]
- chronic fatigue syndrome [Insufficient Evidence]
- colic [Insufficient Evidence]
- COVID-19 [Insufficient Evidence]
- dental caries prevention [Insufficient Evidence]
- dental plaque [Insufficient Evidence]
- depression [Insufficient Evidence]
- diabetes [Insufficient Evidence]
- dysmenorrhea [Insufficient Evidence]
- dyspepsia [Insufficient Evidence]
- endotracheal intubation-related adverse effects [Possibly Effective]
- familial Mediterranean fever (FMF) [Insufficient Evidence]
- hepatitis [Insufficient Evidence]
- H. pylori infection [Insufficient Evidence]
- hypercholesterolemia [Insufficient Evidence]
- hyperkalemia [Insufficient Evidence]
- hyperprolactinemia, antipsychotic-induced [Insufficient Evidence]
- IgA vasculitis [Insufficient Evidence]
- IBS [Insufficient Evidence]
- lichen planus [Insufficient Evidence]
- liver CA [Insufficient Evidence]
- melasma [Insufficient Evidence]
- menopausal sx [Insufficient Evidence]
- muscle cramps [Insufficient Evidence]
- nonalcoholic fatty liver dz [Insufficient Evidence]
- obesity [Insufficient Evidence]
- oral mucositis, chemo- or XRT-related [Insufficient Evidence]
- osteoarthritis [Insufficient Evidence]
- osteoporosis [Insufficient Evidence]
- Parkinson dz [Insufficient Evidence]
- peptic ulcer [Insufficient Evidence]
- physical performance [Insufficient Evidence]
- polycystic ovary syndrome [Insufficient Evidence]
- prostate CA [Insufficient Evidence]
- psoriasis [Insufficient Evidence]
- SLE [Insufficient Evidence]
- tuberculosis [Insufficient Evidence]
- urticaria [Insufficient Evidence]
- vitiligo [Insufficient Evidence]
- xerostomia [Insufficient Evidence]
Reported Doses
Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely
Special Note
- [formulation clarification]
- Info: products generally stdzd to glycyrrhizin content
Effectiveness Ratings
- [see Herb & Supplement Effectiveness Rating Definitions table]
allergic rhinitis
- [Insufficient Evidence]
- Dose: 3 mg/mL intranasally qd; Info: nasal irrigation suspension containing 900 mg licorice extract powder and 3 g iodine-free salt in 300 mL warm water
aphthous ulcer (canker sores)
- [Possibly Effective]
- Dose: apply 0.015-0.229 mg/kg patch topically qd x16 h/day; Alt: apply 1% patch topically qd; 3 mL (5% licorice extract solution plus diphenhydramine) swish/spit qid; 200 mg deglycyrrhizinated licorice powder/200 mL warm water swish/spit qid
atopic dermatitis (eczema)
- [Possibly Effective]
- Dose: apply 1-2% gel topically tid
bleeding
- [Insufficient Evidence]
- Dose: apply 0.09 mg/1 mL spray topically x4; Info: used in episiotomy repair and dental procedures
COVID-19
- [Insufficient Evidence]
- Dose: 300 mg PO qd; Info: used w/ boswellia and standard tx
dental caries prevention
- [Insufficient Evidence]
- Dose: 15 mL (1% solution) swish/spit qhs
depression
- [Insufficient Evidence]
- Dose: 1400 mg PO qd; Info: used w/ standard tx
dysmenorrhea
- [Insufficient Evidence]
- Dose: 750 mg PO bid on days 1-5 of menstrual cycle
dyspepsia
- [Insufficient Evidence]
- Dose: 33.3 mg/1 mL licorice root extract PO tid
endotracheal intubation-related adverse effects
- [Possibly Effective]
- Dose: 97 mg lozenge PO x1 given 30min before intubation; Alt: 0.5 g solution swish/spit x1 given 5min before intubation
H. pylori infection
- [Insufficient Evidence]
- Dose: 380 mg PO bid; Alt: 100 mg PO qd; Info: used w/ or w/o standard tx
hypercholesterolemia
- [Insufficient Evidence]
- Dose: 100 mg PO qd
hyperkalemia
- [Insufficient Evidence]
- Dose: 150 mg PO qd; Alt: 1 g PO qd
IgA vasculitis
- [Insufficient Evidence]
- Dose: 25 mg compound glycyrrhizin PO tid in pts 12 yo and younger; 50 mg compound glycyrrhizin PO tid in pts >12 yo; Info: products containing glycyrrhizin, glycine and methionine; used w/ conventional tx
lichen planus
- [Insufficient Evidence]
- Dose: 40 mL (0.2% glycyrrhizin) IV qd x4wk
melasma
- [Insufficient Evidence]
- Dose: apply 7% cream topically bid
menopausal sx
- [Insufficient Evidence]
- Dose: 330 mg PO tid
nonalcoholic fatty liver dz
- [Insufficient Evidence]
- Dose: 2 g PO qd; Alt: 0.5 g PO bid
oral mucositis, chemo- or XRT-related
- [Insufficient Evidence]
- Dose: apply paste (5 g powder mixed in honey) topically bid plus 500 mg PO bid; Alt: apply film topically qid; Info: used w/ standard tx
Parkinson dz
- [Insufficient Evidence]
- Dose: 136 mg PO bid
peptic ulcer
- [Insufficient Evidence]
- Dose: 2.28-4.56 g deglycyrrhizinated licorice/day PO divided tid
polycystic ovary syndrome
- [Insufficient Evidence]
- Dose: 2.25 g PO qd
psoriasis
- [Insufficient Evidence]
- Dose: apply cream topically bid; Info: used w/ corticosteroid cream
urticaria
- [Insufficient Evidence]
- Dose: 50-75 mg compound glycyrrhizin PO tid; Info: products containing glycyrrhizin, N-acetyl cysteine and glycine
vitiligo
- [Insufficient Evidence]
- Dose: 25-75 mg compound glycyrrhizin PO tid; Info: used w/ standard tx
Copyright © 2024. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.